CRESCENT BIOPHARMA, INC.
CBIO · XNASCIK 1253689fmd_04KXCBDR5ZVH1WBTC7XFZGVDJQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | – | – | – | 10 | 1 | 0 | 0 | – | 11 |
| Research and development | 23 | 24 | 40 | 47 | 45 | 47 | 28 | 20 | 14 | 138 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 32 | 34 | 52 | 61 | 62 | 65 | 47 | 39 | 40 | 163 |
| Operating income | (32) | (34) | (52) | (61) | (52) | (63) | (47) | (39) | (40) | (153) |
| Interest expense | – | – | – | – | – | – | – | – | – | 2 |
| Other non-operating income (expense) | 0 | 1 | – | – | – | – | – | 2 | 2 | – |
| Income before taxes | – | – | – | – | – | – | – | – | – | (152) |
| Income tax expense | – | – | – | – | – | – | – | – | – | 2 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | (154) |
| Net income | (32) | (33) | (48) | (58) | (51) | (63) | (47) | (37) | (38) | (154) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | (133) |